Variations in content of active ingredients causing drug interactions in grapefruit juice products sold in California

Drug Metabolism and Drug Interactions

Volumn 21, Issue 3-4, 2006, Pages 233-243

  Wanwimolruk, Sompon ^a   Marquez, Paul V ^b  

^a LOMA LINDA UNIVERSITY   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Active ingredients; Bergapten; California; Drug interactions; Grapefruit juice; Naringenin; Naringin

Indexed keywords

AURANTIIN; BERGAPTEN; NARINGENIN;

ARTICLE; CONTENT ANALYSIS; FOOD ANALYSIS; FOOD DRUG INTERACTION; FOOD INDUSTRY; GRAPEFRUIT JUICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; UNITED STATES;

EID: 33745650511     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2006.21.3-4.233     Document Type: Article

References (21)

1. Bailey DG, Arnold JMO, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46: 101-110.
2. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99: 2545-2553.
3. Correia MA, Davoll SH, Wrighton SA, Thomas PE. Degradation of rat liver cytochromes P450 3A after their inactivation by 3,5-dicarbethoxy-2,6-dimethyl-4- ethyl-1,4-dihydropyridine: characterization of the proteolytic system. Arch Biochem Biophys 1992; 297: 228-238.
4. Eagling VA, Profit L, Back DJ. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 1999; 48: 543-552.
5. Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001; 69: 14-23.
6. Spahn-Langguth H, Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 2001; 12: 361-367.
7. Kakar SM, Paine MF, Stewart PW, Watkins PB. 6′,7′- Dihydroxybergamottin contributes to the grapefruit juice effect. Clin Pharmacol Ther 2004; 75: 569-579.
8. Edwards DJ, Bellevue FH, Woster PM. Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor in grapefruit juice. Drug Metab Dispos 1996; 24: 128-129.
9. Fukuda K, Ohta T, Yoshiteru O, Ohashi N, Yoshikawa M, Yamazoe Y. Specific CYP3A4 inhibitors in grapefruit juice: furanocoumarin dimers as components of drug interaction. Pharmacogenetics 1997; 7: 391-396.
10. Ho P-C, Saville DJ, Coville PC, Wanwimolruk S. Content of CYP3A4 inhibitors, naringin, naringenin and bergapten in grapefruit and grapefruit juice products. Pharmaceut Acta Helv 2000; 74: 379-385.
11. Fukuda K, Guo L, Ohashi N, Yoshikawa M, Yamazoe Y. Amount and variation in grapefruit juice of the main components causing grapefruit-drug interaction. J Chromatogr 2000; 741: 195-203.
12. Ho P-C, Saville DJ, Wanwimolruk S. Improved HPLC method for determination of a flavonoid naringin in grapefruit juice, without extraction. Pharm Pharmacol Commun 1998; 4: 473-476.
13. Rouseff RL, Martin SF, Youtsey CO. Quantitative survey of narirutin, naringin, hesperidin and neohesperidin in citrus. J Agric Food Chem 1987; 35: 1027-1030.
14. Fuhr U, Kummert AL. The fate of naringin in humans: a key to grapefruit juice-drug interactions? Clin Pharmacol Ther 1995; 58: 365-373.
15. Ross SA, Ziska DS, Zhao K, ElSohly MA. Variance of common flavonoids by brand of grapefruit juice. Fitoterapia 2000; 71: 154-161.
16. Castro WV, Mertens-Talcott S, Rubner A, Butterweck V, Derendrof H. Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies. J Agric Food Chem 2005; 54: 249-255.
17. Lee HS. Objective measurement of red grapefruit juice color. J Agric Food Chem 2000; 48: 1507-1511.
18. Ho P-C, Saville DJ, Wanwimolruk S. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharmaceut Sci 2001; 4: 217-227.
19. Dahan A, Altman H. Food-drug interaction: grapefruit juice augments drug bioavailability - mechanism, extent and relevance. Eur J Clin Nutr 2004; 58: 1-9.
20. Rashid J, McKinstry C, Renwick AG, Dimhuber M, Waller DG, George CF. Quercetin, an in vitro inhibitor of CYP3A4, does not contribute to the interaction between nifedipine and grapefruit juice. Br J Clin Pharmacol 1993; 36: 460-463.
21. Vanakoski J, Mattila MJ, Seppala T. Grapefruit juice does not enhance the effects of midazolam and triazolam in man. Eur J Clin Pharmacol 1996; 50: 501-508.